nicorandil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
nicotinic acid or nicotinoyl alcohol derivatives 1919 65141-46-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicorandil
  • perisalol
  • sigmart
A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.
  • Molecular weight: 211.18
  • Formula: C8H9N3O4
  • CLOGP: -1.80
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 97.04
  • ALOGS: -2.25
  • ROTB: 5

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 4.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.06 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.76 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1984 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 147.21 57.69 37 117 32399 2325532
Intentional overdose 87.03 57.69 20 134 11301 2346630

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arteriospasm coronary 74.84 62.37 13 219 681 1745868
Tonsillar ulcer 68.05 62.37 8 224 19 1746530
Hypotension 67.66 62.37 25 207 29629 1716920
Acute kidney injury 67.26 62.37 26 206 34918 1711631
Fall 65.96 62.37 24 208 27190 1719359

Pharmacologic Action:

SourceCodeDescription
ATC C01DX16 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
VASODILATORS USED IN CARDIAC DISEASES
Other vasodilators used in cardiac diseases
CHEBI has role CHEBI:35620 vasodilator agent
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018977 Micronutrients
MeSH PA D014665 Vasodilator Agents
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Angina pectoris indication 194828000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.97 acidic
pKa2 3.07 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Atrial natriuretic peptide receptor 1 Enzyme EC50 7.20 WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 1 Ion channel IC50 5.95 WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 11 Ion channel IC50 5.89 WOMBAT-PK

External reference:

IDSource
N0000167327 NUI
C0068700 UMLSCUI
D01810 KEGG_DRUG
260456HAM0 UNII
4933 INN_ID
319304004 SNOMEDCT_US
31748 RXNORM
395809002 SNOMEDCT_US
005831 NDDF
47528 PUBCHEM_CID
CHEBI:31905 CHEBI
CHEMBL284906 ChEMBL_ID
DB09220 DRUGBANK_ID
D020108 MESH_DESCRIPTOR_UI
2411 IUPHAR_LIGAND_ID

Pharmaceutical products:

None